Duopharma Biotech Bhd Stock Book Value Per Share
| 7148 Stock | 1.28 0.01 0.78% |
Duopharma Biotech Bhd fundamentals help investors to digest information that contributes to Duopharma Biotech's financial success or failures. It also enables traders to predict the movement of Duopharma Stock. The fundamental analysis module provides a way to measure Duopharma Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Duopharma Biotech stock.
Duopharma |
Duopharma Biotech Bhd Company Book Value Per Share Analysis
Duopharma Biotech's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of Duopharma Biotech Bhd is about 0.0 times. This is 100.0% lower than that of the Healthcare sector and about the same as Pharmaceuticals (which currently averages 0.0) industry. The book value per share for all Malaysia stocks is 100.0% higher than that of the company.
Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
Duopharma Fundamentals
| Return On Equity | 10.93 | |||
| Current Valuation | 1.78 B | |||
| Price To Book | 2.32 X | |||
| Price To Sales | 2.12 X | |||
| Revenue | 639.17 M | |||
| EBITDA | 121.38 M | |||
| Net Income | 82.98 M | |||
| Cash And Equivalents | 31.5 M | |||
| Total Debt | 297.8 M | |||
| Cash Flow From Operations | 43.2 M | |||
| Market Capitalization | 1.56 B | |||
| Total Asset | 1.16 B | |||
| Z Score | 3.0 | |||
| Annual Yield | 0.04 % | |||
| Net Asset | 1.16 B | |||
| Last Dividend Paid | 0.095 |
About Duopharma Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Duopharma Biotech Bhd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Duopharma Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Duopharma Biotech Bhd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Duopharma Stock
Duopharma Biotech financial ratios help investors to determine whether Duopharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Duopharma with respect to the benefits of owning Duopharma Biotech security.